Pharmaceuticals

Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Size and Forecast to 2029: Revenue, Growth, and Trends

December 4, 2025 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the warm autoimmune hemolytic anemia (waiha) treatment market from 2025–2034 with trusted insights from The Business Research Company

How Big Is The Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Size Today And What Will Its Value Be At The End Of 2029?

The warm autoimmune hemolytic anemia (waiha) treatment market size has experienced robust growth in recent years. This market is projected to expand from $0.55 billion in 2024 to $0.6 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 8.7%. Historically, this expansion has been driven by increased healthcare expenditure, a surge in clinical trials dedicated to rare hematologic diseases, the expansion of patient support and advocacy networks, and an increase in the geriatric population.

The market for treating warm autoimmune hemolytic anemia (WAIHA) is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach $0.85 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 9.2%. Key drivers for this projected growth include the rising occurrence of autoimmune conditions, enhanced understanding among medical practitioners, increased use of biologics and specific therapeutic interventions, and the expanded application of off-label medications for autoimmune diseases. Significant developments expected during this period encompass progress in monoclonal antibody treatments, the incorporation of next-generation sequencing (NGS) for diagnostic purposes, breakthroughs in immunology research, and the emergence of technologically advanced drug discovery platforms.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24426&type=smp

Which Key Drivers Are Powering Growth In The Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market?

The escalating healthcare expenditure is anticipated to propel the expansion of the warm autoimmune hemolytic anemia (WAIHA) treatment market moving forward. Healthcare expenditure denotes the total financial resources dedicated to health services, covering prevention, diagnosis, treatment, and disease management, by individuals, governments, and organizations. Advances in medical technology are contributing to the rise in healthcare spending, given that newer diagnostic instruments and treatments frequently incur elevated costs for their development, implementation, and ongoing patient care. This expenditure supports warm autoimmune hemolytic anemia (WAIHA) treatment by financing research, enabling access to advanced diagnostic tools, and ensuring the availability of specialized therapies crucial for managing and controlling the disease. For example, in May 2024, figures from the Office for National Statistics, a UK-based government agency, indicated that long-term health and social care expenditures, in real terms, climbed by 2.8% in 2022, with overall healthcare spending increasing by 5.6% in 2023. Thus, the increasing healthcare expenditure is a key driver for the growth of the warm autoimmune hemolytic anemia (WAIHA) treatment market.

Which Segment Categories Are Driving Maximum Growth In The Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market?

The warm autoimmune hemolytic anemia (waiha) treatment market covered in this report is segmented –

1) By Treatment Type: Corticosteroids, Monoclonal Antibodies, Intravenous Immunoglobulin (IVIG), Blood Transfusions, Splenectomy

2) By Route Of Administration: Oral, Intravenous, Subcutaneous

3) By Patient Demographics: Children, Adults, Geriatric

4) By Therapeutic Area: Primary Autoimmune Disorders, Secondary Autoimmune Disorders, Genetic Predisposition

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Corticosteroids: Prednisone, Dexamethasone, Methylprednisolone

2) By Monoclonal Antibodies: Rituximab, Sutimlimab, Bortezomib

3) By Intravenous Immunoglobulin: Standard IVIG, High-Dose IVIG Therapy, Pooled Plasma-Derived Immunoglobulins

4) By Blood Transfusions: Leukoreduced RBC Transfusions, Emergency Transfusions, Phenotypically Matched RBC Transfusions

5) By Splenectomy: Laparoscopic Splenectomy, Prophylactic Treatments Post-Splenectomy, Open Splenectomy

What Key Trends Are Driving Growth In The Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market?

Leading companies in the warm autoimmune hemolytic anemia (WAIHA) treatment market are concentrating on developing innovative solutions, such as monoclonal antibodies, to address existing clinical needs and enhance patient outcomes. Monoclonal antibodies are laboratory-engineered proteins designed to target specific immune cells or pathways, thereby reducing the destruction of red blood cells in warm autoimmune hemolytic anemia. For instance, in July 2023, IASO Biotechnology, a China-based biopharmaceutical company, announced that its IASO-782 Injection received U.S. Food and Drug Administration (FDA) approval for use in clinical studies within the United States for autoimmune hematological conditions, including warm autoimmune hemolytic anemia (WAIHA) and primary immune thrombocytopenia (ITP). This fully human monoclonal antibody targets CD19 and features Fc mutations designed to increase ADCC activity while maintaining other Fc functions. It works by selectively depleting CD19+ B cells, plasma blasts, and certain plasma cells, which are responsible for generating auto-reactive antibodies. Given its distinct mechanism, IASO-782 may offer a treatment option for autoimmune illnesses driven by pathogenic B and plasma cells, such as ITP and AIHA.

Who Are The Leading Companies Driving The Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market?

Major companies operating in the warm autoimmune hemolytic anemia (WAIHA) treatment market are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Sanofi S.A., AstraZeneca Plc, Novartis AG, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Agios Pharmaceuticals Inc., Incyte corporation, Mallinckrodt Pharmaceuticals, Hutchison Medipharma Limited, BioCryst Pharmaceuticals Inc., Xencor Inc., Annexon Inc., Rigel Pharmaceuticals Inc., Apellis Pharmaceuticals Inc., Momenta Pharmaceuticals Inc., Immunovant Inc., Zenas BioPharma Inc., Alexion Pharmaceuticals Inc., Mitsubishi Tanabe Pharma Corporation.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/warm-autoimmune-hemolytic-anemia-waiha-treatment-global-market-report

Which Region Holds The Largest Share In The Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Today?

North America was the largest region in the warm autoimmune hemolytic anemia (WAIHA) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the warm autoimmune hemolytic anemia (WAIHA) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=24426&type=smp

Browse Through More Reports Similar to the Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market 2025, By The Business Research Company

Autoimmune Disease Diagnosis Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/autoimmune-disease-diagnosis-global-market-report

Granulocyte Colony Stimulating Factors Market 2025

https://www.thebusinessresearchcompany.com/report/granulocyte-colony-stimulating-factors-market

Drug Delivery Devices Market 2025

https://www.thebusinessresearchcompany.com/report/drug-delivery-devices-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795